Search research articles
Contact Us
Filters
Showing results (1-10 of 91) with videos related to
Page
of 10
Sort By:
ACS Chemical Neuroscience
|
June 10, 2015
Current hypotheses of lithium's mechanism of action as a neuropsychiatric medication
Galila Agam
Neuropsychiatric Disease and Treatment
|
October 8, 2015
Mitochondrial dysfunction in psychiatric morbidity: current evidence and therapeutic prospects
Lilach Toker, Galila Agam
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
August 19, 2003
Possible role of 3'(2')-phosphoadenosine-5'-phosphate phosphatase in the etiology and therapy of bipolar disorder
Galila Agam, Galit Shaltiel
Frontiers in Neuroscience
|
September 18, 2014
Why lithium studies for ALS treatment should not be halted prematurely
Galila Agam, Adrian Israelson
Journal of Molecular Neuroscience : MN
|
July 16, 2008
Perinatal oxygen restriction does not result in reduced rat frontal cortex synaptophysin protein levels at adulthood as opposed to postmortem findings in schizophrenia
Carmit Nadri, Galila Agam
Journal of Medicinal Chemistry
|
February 10, 2015
Calbindin D28k and S100B have a similar interaction site with the lithium-inhibitable enzyme inositol monophosphatase-1: a new drug target site
Galila Agam, Orna Almog
ACS Chemical Neuroscience
|
June 3, 2014
Lithium, inositol and mitochondria
Lilach Toker, Galila Agam
International Journal of Molecular Sciences
|
January 8, 2025
Lithium, Inflammation and Neuroinflammation with Emphasis on Bipolar Disorder-A Narrative Review
Odeya Damri, Galila Agam
Discovery Medicine
|
August 14, 2010
Bipolar disorder: Neurochemistry and drug mechanisms
R H Belmaker, Galila Agam
The Israel Journal of Psychiatry and Related Sciences
|
August 6, 2010
Editorial: Etiological hypotheses of mental disorders at the molecular level
Galila Agam, Dorit Ben-Shachar
Page
of 10
Search research articles
Search
Showing results (1-10 of 91) with videos related to
Sort By:
Page
of 10
ACS Chemical Neuroscience
|
June 10, 2015
Current hypotheses of lithium's mechanism of action as a neuropsychiatric medication
Galila Agam
Neuropsychiatric Disease and Treatment
|
October 8, 2015
Mitochondrial dysfunction in psychiatric morbidity: current evidence and therapeutic prospects
Lilach Toker, Galila Agam
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
August 19, 2003
Possible role of 3'(2')-phosphoadenosine-5'-phosphate phosphatase in the etiology and therapy of bipolar disorder
Galila Agam, Galit Shaltiel
Frontiers in Neuroscience
|
September 18, 2014
Why lithium studies for ALS treatment should not be halted prematurely
Galila Agam, Adrian Israelson
Journal of Molecular Neuroscience : MN
|
July 16, 2008
Perinatal oxygen restriction does not result in reduced rat frontal cortex synaptophysin protein levels at adulthood as opposed to postmortem findings in schizophrenia
Carmit Nadri, Galila Agam
Journal of Medicinal Chemistry
|
February 10, 2015
Calbindin D28k and S100B have a similar interaction site with the lithium-inhibitable enzyme inositol monophosphatase-1: a new drug target site
Galila Agam, Orna Almog
ACS Chemical Neuroscience
|
June 3, 2014
Lithium, inositol and mitochondria
Lilach Toker, Galila Agam
International Journal of Molecular Sciences
|
January 8, 2025
Lithium, Inflammation and Neuroinflammation with Emphasis on Bipolar Disorder-A Narrative Review
Odeya Damri, Galila Agam
Discovery Medicine
|
August 14, 2010
Bipolar disorder: Neurochemistry and drug mechanisms
R H Belmaker, Galila Agam
The Israel Journal of Psychiatry and Related Sciences
|
August 6, 2010
Editorial: Etiological hypotheses of mental disorders at the molecular level
Galila Agam, Dorit Ben-Shachar
Page
of 10